[Skip to content]

tab rollover pre-load tab rollover pre-load tab rollover pre-load tab rollover pre-load tab rollover pre-load tab rollover pre-load
Wednesday 27 October 2021
Salford GP Header Montage
Latest News:
RSS icon
Medicine, tablets, pills


This is an electronic version of our Formulary written in conjunction with the Medicine Management Committee and the Pharmacy department.   The purpose of the Formulary is:

  • To promote safe, rational and cost effective prescribing within the Trust.
  • To help select the most appropriate drug amongst the many available.


This formulary is intended to act as a rapid reference source.  It is intended for the guidance of medical practitioners, nurses and other healthcare workers.


For local GPs and Non-medical prescribers working in the community there is the Greater Manchester Joint Formulary produced by the Greater Manchester Medicines Management Group (GMMMG).  The formulary ensures that patients receive seamless care across the primary-secondary care interface and reduces the need for switching programmes. All medicines recommended for use in the NHS in a NICE Technology Assessment (TA) are approved for use in Greater Manchester, the GMMMG site provides a list of medicines with a positive recommendation from  NICE and provides links to these TAs in the GMMMG formulary.  In the SRFT formulary below all the drugs with a positive NICE TA that are applicable to SRFT are included in the formulary.


How to use

All medicines are listed alphabetically using the generic name where possible.  Some brand names are used.


  1. Type the drug name in the 'Keywords' box

  2. Click on the 'Search' button

  3. Within the results, click on the 'generic name' of the medicine you are looking for.

  4. Click on the 'Link' - this will take you to further information that talks about that medicine. 



Drug NameBNF CategoryComment / Usage RestrictionsDetails
Omalizumab3.4.2 Allergy immunotherayApproved for dermatology use in atopic dermatitis via an IFR. Unlimited IFRs approved. Funding still required via CCG though. Contact medicines management team in pharmacy. Approved July 2013 
OmalizumabSee online BNFTo treat chronic spontaneous urticaria. Approved September 2015 As per licensed indication (NICE TA 339) for initiation by the Immunology Consultants.  
Omalizumab3.4.2 Allergen immunotherapyAsthma -respiratory team in line with NICE guidance 
Omega-3-Acid Ethyl Esters2.12 Fish oilsLipid Clinic for hypertriglyceridaemia only. No longer used in post MI setting. 
Omeprazole Capsules1.3.5 Proton pump inhibitors - see Salford PPI Strategy and GuidelinesFirst line PPI - Omeprazole MUPS available if patients require a soluble option.  Omeprazole MUPS also available for use in PANDA (in line with choice at RMCH). 
Ondansetron 8mg Oral Tablets4.6 Drugs used in nausea and vertigoHaematology and Oncology only 
Ondansetron Injection4.6 Drugs used in nausea and vertigoHaematology, Oncology and third line in PONV only 
Orphenadrine4.9.3 Drugs used in essential tremor, chorea, tics and related disorders  
Oseltamivir5.3.4 Antiviral drugsUse in accordance with Trust Influenza A guidelines and NICE guidance 
Osvaren (Calcium Acetate, Heavy Magnesium) phosphate binding agentsFor use in renal patients (if commenced on these agents this must be by the renal team or on their recommendation) in line with the guideline for chronic kidney disease mineral bone disorder. Approved March 2012  


All material in this section is aimed at health professionals, but is information currently held within the public domain.   Members of the public seeking advice on medicine-related matters are encouraged to speak with their GP, pharmacist or nurse, or contact NHS Direct on 0845 46 47.